血液恶性瘤中的TGF-β:分子功能和临床应用
Ruiyang Li1, Fang Wei2, Mengbo Yang1
1The First Clinical Medical College, Shanxi Medical University, Taiyuan, Shanxi, China.
Frontiers in immunology
|March 16, 2026
概括
转化生长因子-β (TGF-β) 是血液恶性瘤中的关键细胞因子,促进免疫抑制和瘤生长. 准TGF-β信号通路显示出改善这些癌症免疫疗法反应的前景.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 转化生长因子-β (TGF-β) 是一种多功能细胞因子,对免疫常态稳定至关重要.
- TGF-β在血液恶性瘤中表达高,有助于免疫抑制瘤微环境.
- 它调节免疫细胞功能,瘤细胞增殖,亡和耐药性.
研究的目的:
- 审查TGF-β的分子机制.
- 讨论血液恶性瘤中的免疫细胞中的TGF-β功能.
- 总结TGF-β向疗法的临床进展和挑战.
主要方法:
- 关于分子机制,免疫细胞功能和临床试验的文献综述.
- 对TGF-β在白血病,淋巴瘤和多发性髓瘤中的作用的分析.
- 对TGF-β信号通路抑制剂的当前研究的综合.
主要成果:
- TGF-β通过抑制效应T细胞激活来增强免疫抑制.
- 在临床前模型中,TGF-β信号通路向改善了免疫治疗反应.
- 几种TGF-β向剂正在临床试验的早期阶段.
结论:
- TGF-β在血液性恶性瘤的发病和免疫逃避中发挥着重要作用.
- 向TGF-β提供了一个有前途的策略,以提高免疫疗法的疗效.
- 需要进一步的临床研究来克服TGF-β向疗法的挑战.
相关概念视频
Role of Hematopoietic Growth Factors
4.3K
Hematopoietic growth factors are molecules that regulate the differentiation rate of hematopoietic stem cells (HSCs). Erythropoietin (EPO), primarily produced by the kidneys, plays a crucial role in erythrocyte production. When oxygen levels in the blood are low, EPO is released into the bloodstream, reaching the bone marrow, where it stimulates HSCs to differentiate and mature into erythrocytes, which are vital for oxygen transport.
Thrombopoietin (TPO), mainly released by the liver,...
Thrombopoietin (TPO), mainly released by the liver,...
4.3K
TGF - β Signaling Pathway
10.8K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.8K
General Transcription Factors
7.5K
Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
7.5K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
63
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
63
Transcription Factors
83.6K
Tissue-specific transcription factors contribute to diverse cellular functions in mammals. For example, the gene for beta globin, a major component of hemoglobin, is present in all cells of the body. However, it is only expressed in red blood cells because the transcription factors that can bind to the promoter sequences of the beta globin gene are only expressed in these cells. Tissue-specific transcription factors also ensure that mutations in these factors may impair only the function of...
83.6K
Regulation of Hematopoietic Stem Cells
4.3K
All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...
4.3K


